NCT01426100CompletedPhase 3
A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Fixed Dose Combination of Telmisartan and S-Amlodipine(CKD-828) Versus Telmisartan Monotherapy in Hypertensive Patients Inadequately Controlled by Telmisartan Monotherapy
Chong Kun Dang Pharmaceutical18 sites in 1 country183 target enrollmentStarted: August 2011Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 183
- Locations
- 18
- Primary Endpoint
- Mean Sitting Diastolic Blood Pressure (MSDBP)
Study Overview
Brief Summary
The aim of the present study is to evaluate the efficacy and safety of two dose combination of Telmisartan/S-Amlodipine (40/2.5mg and 40/5mg) compared with telmisartan monotherapy (80mg) in hypertensive patients inadequately controlled by telmisartan monotherapy.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Care Provider, Investigator)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •age 18 years or older
- •diagnosis of essential hypertension and blood pressure not adequately controlled(inadequate control defined as seated diastolic blood pressure(DBP)>= 90mmHg if on existing antihypertensive treatment of seated DBP >= 100mmHg if treatment naive)
- •failure to respond to four weeks treatment with telmisartan 40mg(failure to respond defined as seated DBP >= 90mmHg)
- •willing and able to provide written informed consent
Exclusion Criteria
- •mean seated DBP >= 120mmHg and/or mean seated SBP >= 200mmHg during run-in treatment or mean seated DBP >= 120mmHg and/or mean seated SBP >= 180mmHg at the randomization visit
- •known or suspected secondary hypertension(ex. aortic coarctation, Primary hyperaldosteronism, renal artery stenosis, pheochromocytoma)
- •has severe heart disease(Heart failure NYHA functional class 3, 4), unstable angina or myocardial infarction, arrhythmia within the past three months
- •has cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months
- •Type I Diabetes Mellitus, Type II Diabetes Mellitus with poor glucose control as defined by fasting glucosylated hemoglobin(HbA1c) > 8%
- •nown severe or malignant retinopathy
- •hepatic or renal dysfunction as defined by the following laboratory parameters: AST/ALT > UNL X 2, serum creatinine > UNL X 1.5
- •acute or chronic inflammatory status need to treatment
- •need to additional antihypertensive drugs during the study
- •need to concomitant medications known to affect blood pressure during the study
- •history of angioedema related to ACE inhibitors or Angiotensin II Receptor Blockers
- •known hypersensitivity related to either study drug
- •history of drug or alcohol dependency within 6 months
- •any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of investigational products(ex. gastrointestinal tract surgery such as gastrectomy, gastroenterostomy or bypass, active inflammatory bowel syndrome within 12 months prior to screening, gastric ulcers need to treatment, gastrointestinal/rectal bleeding, impaired pancreatic function such as pancreatitis, obstructions of the urinary tract or difficulty in voiding
- •administration of other study drugs within 30 days prior to randomization
- •premenopausal women(last menstruation < 1year) not using adequate contraception, pregnant or breast-feeding
- •history of malignancy including leukemia and lymphoma within the past 5 years
- •in investigator's judgment
Arms & Interventions
CKD-828 40/2.5mg
Experimental
Intervention: CKD-828 40/2.5mg (Drug)
CKD-828 40/5mg
Experimental
Intervention: CKD-828 40/5mg (Drug)
Telmisartan 80mg
Active Comparator
Intervention: Telmisartan 80mg (Drug)
Outcomes
Primary Outcomes
Mean Sitting Diastolic Blood Pressure (MSDBP)
Time Frame: After 8 weeks of treatment
Secondary Outcomes
- Mean Sitting Diastolic Blood Pressure (MSDBP)(After 4 weeks of treatment)
- Mean Sitting Systolic Blood Pressure (MSSBP)(After 4 weeks and 8 weeks of treatment)
- Response rate(After 4 weeks and 8 weeks of treatment)
- Control rate(After 4 weeks and 8 weeks of treatment)
Investigators
Study Sites (18)
Loading locations...
Similar Trials
Unknown
Phase 3
Efficacy and Safety of TELMINUVO to Stage 2 HypertensionHypertensionNCT01983735Chong Kun Dang Pharmaceutical200
Terminated
Phase 2
Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular DegenerationAge-Related MaculopathyNCT01577381Pfizer10
Completed
Phase 2
Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic EndometriosisEndometriosisNCT01728454Repros Therapeutics Inc.60
Active, not recruiting
Phase 3
Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL PatientsSplenic Marginal Zone LymphomaNCT05735834International Extranodal Lymphoma Study Group (IELSG)122
Active, not recruiting
Phase 2
Tucatinib+Trastuzumab+Eribulin in HER2+ MBCPretreated Unresectable Locally Advanced or Metastatic HER2+ Breast CancerBreast CancerNCT05458674Criterium, Inc.17